Azmi Nabulsi - Jan 19, 2022 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role
Chief Operating Officer
Signature
/s/ Larry Miller, Attorney-in-Fact for Azmi Nabulsi
Stock symbol
PHAT
Transactions as of
Jan 19, 2022
Transactions value $
$0
Form type
4
Date filed
1/21/2022, 05:52 PM
Next filing
May 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Award $0 +19.5K +1038.34% $0.00 21.4K Jan 19, 2022 Direct F1, F2
holding PHAT Common Stock 843 Jan 19, 2022 by 401(k)
holding PHAT Common Stock 766K Jan 19, 2022 by Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHAT Stock Option (Right to Buy) Award $0 +97.5K $0.00 97.5K Jan 19, 2022 Common Stock 97.5K $15.21 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted on January 19, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2 Includes 1,425 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2021 and January 2022 and 453 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan which were inadvertenly omitted from the most recent Form 4.
F3 The stock option will vest with respect to 25% of the shares of common stock on January 19, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.